肝硬化代谢因素:孟德尔的随机化研究
Xiaobing Wang1, Yu Ni, Ziwen Wang
1Department of Gastroenterology, The First Affiliated hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Medicine
|January 14, 2025
概括
这项研究发现,氨酸氨基转移酶 (ALT) 和体重指数 (BMI) 的升高因果上会增加肝硬化风险. 控制ALT水平可能是预防肝病进展的关键.
科学领域:
- 遗传学 是一个遗传学.
- 代谢疾病 代谢疾病
- 肝病学 肝病学是一种肝病学.
背景情况:
- 肝硬化是一种慢性肝病,其特征是炎症和纤维化.
- 早期识别风险因素对于干预至关重要.
- 遗传易感性和代谢因素在肝硬化发展中起作用.
研究的目的:
- 通过全基因组关联研究 (GWAS) 研究14种代谢因素对肝硬化风险的因果关系.
- 通过在单独的GWAS数据集中的复制分析来验证发现.
- 为了确定影响肝硬化的主要代谢因素,为潜在的预防策略.
主要方法:
- 采用了两个样本的孟德尔随机化 (MR) 分析.
- 利用了公开可用的GWAS肝硬化和代谢因素的数据.
- 逆方差加权 (IVW) 方法是因果推理的主要统计方法.
主要成果:
- 氨酸氨基转移酶 (ALT) 和体重指数 (BMI) 显示出与肝硬化风险有显著的积极因果关系.
- 在一个GWAS中,禁食胰岛素水平也与肝硬化风险有关.
- 高血压在一个GWAS中显示出与肝硬化风险的负因果关系.
结论:
- 升高的ALT水平与肝硬化风险增加有因果关系.
- 有效控制ALT可能是预防肝硬化的一个重要策略.
- 需要进一步的研究来证实其他代谢因素和肝硬化之间的因果关系.
相关概念视频
Liver Regeneration
4.2K
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
4.2K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
386
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
386
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
274
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
274
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
160
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160
Cirrhosis I: Introduction
30
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
30
Cirrhosis II: Pathophysiology
49
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
49


